Resistance of Neisseria gonorrhoeae to antibiotics has developed rapidly in recent years, leading to increased efforts to identify novel antimicrobials. Researchers at Nationwide Children's Hospital and The Ohio State University have found that AR-12, a drug used in oncology, has antimicrobial properties in the context of N. gonorrhoeae infection of normal human mucosa. Further, AR-12's antimicrobial activity targets the human pathways required for infection, not the pathogen itself, suggesting that it is unlikely to encourage the development of bacterial resistance mechanisms.